Allogene Therapeutics Share Price Today

Allogene presents ALLO-329 Phase 1 data at ACR Convergence

Allogene Therapeutics presented preliminary safety, efficacy, and translational data from its Phase 1 RESOLUTION trial of ALLO-329 at ACR Convergence in Orlando, Florida. ALLO-329 is an investigational, next-generation, off-the-shelf allogeneic CAR T product designed for autoimmune disease, with no high-grade toxicities or ICANS cases reported to date. The ALPHA3 trial targeting MRD-positive lymphoma is accelerating enrollment, with completion targeted by year-end 2027 and a clinical update scheduled for mid-2027. CFO Jeff Parker retired following the earnings call; Annie Yoshiyama will oversee financial operations during the search for a new CFO. Allogene's Dagger technology in ALLO-329 aims to reduce reliance on chemotherapy-based lymphodepletion in autoimmune disease treatment.

Allogene Therapeutics CFO Geoffrey Parker To Retire In November 2026

Allogene Therapeutics CFO Geoffrey Parker to retire on November 6, 2026. Parker will lead finance team during external search for successor. Company develops allogeneic CAR T products for cancer and autoimmune disease.

Allogene Therapeutics to speak at Citi Biopharma Back to School Conference

Allogene Therapeutics to present at Citi Biopharma Back to School Conference. Session scheduled for September 9 at 5:00 am PT / 8:00 am ET. Webcast available on company website with 30-day replay access. Company focuses on allogeneic CAR T cell therapies for cancer.

Allogene Therapeutics Q2 2026: EPS beats, cash extends to 2029

Allogene Therapeutics reported Q2 2026 results with an EPS of $(0.13), beating estimates. Revenue of $4.64 million significantly exceeded expectations. With $423.6 million in cash, the company projects a runway into 2029. Key clinical updates include RMAT designation for cema-cel and continued enrollment in the ALLO-329 autoimmune trial.

Allogene Therapeutics files prospectus for $500 million offering

Allogene Therapeutics has filed an SEC prospectus for a $500 million offering. The source material is limited to this regulatory disclosure, with no additional financial data, operational updates, or analyst estimates provided for analysis.

Allogene Therapeutics Q2 Results: Earnings Call Set for Aug 12

Allogene Therapeutics, Inc. will report second quarter 2026 financial results and provide a business update on August 12, 2026, after the close of the market. The clinical-stage biotechnology company, which develops allogeneic CAR T products for cancer and autoimmune disease, will host a conference call and webcast to discuss the findings. Investors can access the listen-only webcast via the company's website, with a replay available for approximately 30 days.